Breaking News

Emergent Technologies, Xencor Enter License Agreement

January 12, 2016

Provides exclusive rights to use a TCRm monoclonal antibody against Receptor target NY-ESO1

Emergent Technologies’ portfolio company, Receptor Logic, has entered into an exclusive License Agreement providing Xencor, Inc. with exclusive worldwide rights to use a T-Cell Receptor Mimic (TCRm) monoclonal antibody against the target NY-ESO1, developed by Receptor Logic, for cancer treatment.

“Our expertise in cancer target identification, when coupled with our development of TCRm monoclonal antibodies to cancer targets, provides a powerful pipeline for immuno-oncology drug development,” said chief scientist William Hildebrand, Ph.D. “By identifying HLA/cancer antigen targets and making TCRm monoclonal antibodies to these targets, we provide industry partners with a steady stream of more personalized cancer therapeutics.”

“This agreement with Xencor reflects the significant value of our platform as we continue to advance into personalized medicine,” said Thomas Harlan, chief executive officer of Receptor Logic and its related company, Pure MHC. “We‘re excited to provide one of our TCRm antibodies to Xencor to assist the company in its cancer therapeutic development efforts.”

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems